2012
Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy?
Prescott CR, Sklar CA, Lesser RL, Adelman RA. Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy? Journal Of Neuro-Ophthalmology 2012, 32: 51-53. PMID: 22269947, DOI: 10.1097/wno.0b013e318240596e.Peer-Reviewed Original ResearchConceptsNonarteritic anterior ischemic optic neuropathyAnterior ischemic optic neuropathyIschemic optic neuropathyVisual acuityIntravitreal bevacizumabOptic neuropathyTreatment optionsIntravitreal bevacizumab injectionEffective treatment optionVisual field defectsBevacizumab injectionFellow eyesClinical outcomesRetrospective studyTreatment modalitiesNatural courseField defectsPatientsDecreased acuitySmall seriesAcuityBevacizumabProfound lossVisual fieldNeuropathy
2011
The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
Lee ST, Adelman RA. The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab. Journal Of Ocular Pharmacology And Therapeutics 2011, 27: 611-614. PMID: 21810026, DOI: 10.1089/jop.2011.0045.Peer-Reviewed Original ResearchConceptsRecurrent central serous chorioretinopathyMean central macular thicknessCentral macular thicknessCentral serous chorioretinopathyPreinjection visual acuityVisual acuityOptical coherence tomographyIntravitreal bevacizumabSerous chorioretinopathyTreatment optionsLow-risk treatment optionYale Eye CenterIntravitreal bevacizumab injectionRetrospective case seriesEffective treatment optionLong-term efficacySub-retinal fluidNumber of injectionsFluorescein angiography imagingBevacizumab injectionRecurrent diseaseMacular thicknessMonth 3Month 6Case series
2010
Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
Adelman RA, Zheng Q, Mayer HR. Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. Journal Of Ocular Pharmacology And Therapeutics 2010, 26: 105-110. PMID: 20187807, DOI: 10.1089/jop.2009.0076.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInjections, IntraocularIntraocular PressureMacular DegenerationMaleOcular HypertensionRanibizumabRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVitreous BodyConceptsAge-related macular degenerationPersistent ocular hypertensionOcular hypertensionIntraocular pressureIntravitreal bevacizumabRanibizumab injectionsIntravitreal injectionPrevious diagnosisGlaucoma/ocular hypertensionIntravitreal anti-VEGF injectionsAnti-VEGF injectionsIntravitreal bevacizumab injectionPostinjection intraocular pressurePreinjection intraocular pressureMultiple intravitreal injectionsTertiary referral centerRetrospective case seriesElevated intraocular pressureBevacizumab injectionIntravitreal ranibizumabReferral centerCase seriesVEGF injectionIOP increaseYAG capsulotomy